1. Ala-Fossi SL, Maenpaa J, Blauer M, Tuohimaa P, Punnonen R. (2000). Inhibin A, B and pro-alpha C in serum and peritoneal fluid in postmenopausal patients with ovarian tumors, Eur J Endocrinol 142, 334–9.
2. Ardekani AM, Hitt B, Brown MR, Fishman DA, Mills G, Liotta L, Petricoin EF, Kohn EC. (2001). A high throughput proteomic approach to serum marker development for discrimination between ovarian cancer patients and unaffected individuals, Proc Soc Gynecol Oncol 32: 102.
3. Avail Lundqvist E, Nordstrom L, Sjovall K, Eneroth P. (1989). Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies, Eur J Gynaecol Oncol 10, 395–405.
4. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. (1999). Serum sErb B1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Can Epid Bio Prey 8, 129–37.
5. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. (1999). Serum sErbBl and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Cancer Epidemiol Biomarkers 8, 129–37.